A ntihypertensive drug therapy substantially reduces the risk of hypertension-related morbidity and mortality. 1 Information to guide the initial choice of pharmacotherapy for hypertensive patients was limited before the publications concerning the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT began in February 1994 and ended in March 2002. In April 2000, ALLHAT published early results that indicated an increased risk of heart failure associated with use of ␣-blocker doxazosin mesylate compared with diuretics. 2 These findings resulted in early discontinuation of the doxazosin treatment arm and a change in recommendations for use of ␣-blockers. 3 In December 2002, ALLHAT published the major study findings, which showed that cardiovascular outcomes were the same in hypertensive patients treated with thiazide-type diuretics as in those treated with calcium channel bockers (CCB) or angiotensin-converting enzyme (ACE) inhibitors. 4 Because thiazide-type diuretics are lower in cost than drugs of other classes, these findings led to a strong recommendation that they should be the first step in antihypertensive therapy for uncomplicated hypertension in most patients. 5 It is of interest to know how the ALLHAT publications affected prescribing patterns for antihypertensive agents.
A recent Canadian study showed that thiazide-type diuretics gained in market share after the ALLHAT publication for new patients older than 65 years (referred to here as new prescriptions). 6 The prescribing patterns for all patients (referred to here as all prescriptions) were not analyzed. However, examining of all prescriptions is very important because new prescriptions account for only a small percentage of all prescriptions for any given time interval. Stafford et al reported that the national trend in ␣-block prescribing declined after its early stopping from ALLHAT for both new and all prescriptions, 7 but the impact of the ALLHAT publication in December 2002 was not addressed. We assessed prescribing patterns of six classes of antihypertensive agents both for new and for all prescriptions after the ALLHAT publications in a large health maintenance organization (HMO), namely, Kaiser Permanente Southern California (KPSC).
Methods

Study Population
Our analysis used computer-stored information from the KPSC pharmacy system for the period between January 1, 1996, and December 31, 2003. The system contains information on members' prescriptions filled at KPSC pharmacies. Among KPSC members, 92% have prescription drug coverage and can obtain prescriptions for a small copayment if filled in KPSC pharmacies but must pay full prices out of pocket if filled elsewhere. This study was approved by the Kaiser Permanente Institutional Review Board.
Study Design
The study assessed prescribing patterns for antihypertensive drugs in six classes: thiazide-type diuretics, ACE inhibitors or angiotensin receptor blockers (ARB), CCB, ␤-blockers, ␣-blockers and other-type antihypertensive diuretics including loop diuretics and potassium-sparing diuretics. Any combinations of these antihypertensive drugs were not included in our analysis because of their low percentages in the total prescriptions. The monthly total number of prescriptions for each class of antihypertensive agents was calculated. We then calculated the relative percentage of each class of antihypertensive agent classes by dividing the total number of prescriptions for each class into the total number of prescription including all classes. New prescriptions were defined as prescriptions to patients who had not filled any prescriptions for any of these antihypertensive agents in the previous 365 days. 6 
Statistical Analyses
A stepwise auto-regressive forecasting model was used for time series analysis. Predicted relative percentages and 95% confidence intervals (CI) for each antihypertensive drug class were calculated for the first 6 months of 2003. In each class, the statistical significance of difference between predicted and observed percentages was tested based on the model. A value of P Ͻ .05 (two-tailed test) was declared as statistically significant. Table 1 shows the total number of all and new prescrip- tions by antihypertensive agent class and age group. The ACE inhibitors or ARB and ␤ blockers are most common prescribed. Of new prescriptions, 47.6% were prescribed to patients Ͻ55 years of age. For all prescriptions, only 24.9% were to patients Ͻ55 years of age. The monthly number of prescriptions is shown in Fig. 1 . The number of all prescriptions increased linearly but the number of new prescriptions only slightly increased. New prescriptions accounted for only about 4.3% of all prescriptions. Figure 2A shows the relative percentage of new prescriptions for each antihypertensive agent class. Before the ALLHAT publication in December 2002, both ␤ blockers and ACE inhibitors or ARB had an overall linear increasing trend, whereas the trend was decreasing for other four classes. Prescribing patterns changed immediately after the ALLHAT publication. The percentage of thiazide-type diuretics increased and continued to increase throughout 2003, whereas the percentages of ␤-blockers and ACE inhibitors or ARB fell. Table 2 presents the observed percentages, predicted percentages, 95% CI, and P values for each class of new prescriptions during the first 6 months of 2003. Compared with predicted percentages, the observed percentages of thiazide-type diuretics were statistically significantly higher and those of ␤-blockers were statistically significantly lower (for each month, P Ͻ .05 for both classes). Figure 2B shows the relative percentage of each class of antihypertensive agents for all prescriptions. The percentage of thiazide-type diuretics for all prescriptions also immediately increased after the ALLHAT publication. The percentage of ACE inhibitors or ARB increased linearly in the entire study period, and this increase was not altered in relation to the ALLHAT publication. ␤-Blockers showed an overall linear increasing trend before the publication, but the percentage of ␤-blockers became constant after the publication. Use of CCB decreased linearly during the entire time interval. In contrast, use of ␣-blockers remained constant before January 2000 and then decreased linearly after January 2000, the early time of stopping ALLHAT. Table 3 presents the observed percentages, predicted percentages, 95% CI and P values for each class of all prescriptions during the first 6 months of 2003. During the first 6 months of 2003, the percentages of thiazide-type diuretics were statistically significantly higher compared with the predicted values (for all months except January, P Ͻ .05; for January, P ϭ .06). The percentages of ␤-blockers were statistically significantly lower compared with the predicted values (P Ͻ .05 for all months).
Results
Prescribing Patterns of Antihypertensive Drugs for New Prescriptions
Prescribing Patterns of Antihypertensive Drugs for All Prescriptions
Discussion
Our data show that the results of ALLHAT publications had a large effect on KPSC prescribing patterns for antihypertensive agents. All prescriptions for ␣-blockers were immediately decreased after the National Heart, Lung, and Blood Institute (NHLBI) committee discontinued the doxazosin (␣-blocker) treatment in ALLHAT in January 2000. This finding is consistent with the results based on national prescription claims. 7 On the other hand, at KPSC, new prescriptions for ␣-blockers were not affected by the ALLHAT publication. This may be due to the low use of ␣-blockers for new prescriptions in KPSC members. This percentage was small compared with that of the national population.
Our data also show that the percentage of thiazidetype diuretics immediately and significantly increased and was offset by decreases in other classes of antihypertenive agents for both new and all prescriptions after the ALLHAT publication in December 2002. Although the Canadian study also showed a significant gain in thiazide-type diuretics, 6 our analysis of KPSC prescribing patterns for these antihypertensive agents differs from the Canadian analysis in several ways. First, we
FIG. 2. Relative percentage of antihypertensive agents for new prescriptions (A) and for all prescriptions (B).
analyzed two additional antihypertensive agent classes, namely, ␣-blockers and other antihypertensive diuretics, to reflect more exactly prescriptions in the antihypertensive agent market. Second, in addition to analyzing new prescriptions, we also calculated the percentage of the six antihypertensive agent classes for all prescriptions. The prescribing pattern of all prescriptions reflects the actual KPSC use of antihypertensive agents more than that of new prescriptions because new prescriptions account for only about 4.3% of all prescriptions. Again, we observed a significant gain in prescriptions for thiazide-type diuretics and significant change in ␤-blockers after the ALLHAT main publication. This contrasts with the Canadian analysis. In the Canadian analysis, the relative percentage gain of thiazide-type diuretics for new prescriptions was mainly attributable to a drop in ACE inhibitors or ARB. In KPSC, the gain of thiazide-type diuretics was attributable to a change in ␤-blockers rather than ACE inhibitors or ARB. Our study coincided with a KPSC-specific program, initiated in 2002 to 2003, to promote the use of ACE inhibitors or ARB in patients at high risk for cardiovascular disease and in patients with diabetes based on the findings of the Heart Outcomes Prevention Evaluation (HOPE) study. 8 Finally, our analysis was based on prescriptions in younger as well as older Abbreviations as in Table 1 .
persons, whereas the data in the previous study 6 was limited to individuals Ͼ65 years of age.
The KPSC site is one of the Ͼ600 sites where ALLHAT was conducted. However, there was no special educational effort undertaken specific to the ALL-HAT results during the study period. All of the specific drugs used in ALLHAT were available in the KPSC formulary without restrictions. We believe that the prescribing pattern changes in our study population were mainly affected by the ALLHAT publications.
Our study has several limitations. First, the study reflects practice in one HMO, and experience in this HMO may not be representative of all settings. Second, these antihypertensive drug agents can be used for conditions other than hypertension. For example, ␤-blockers, CCB, and ACE inhibitors are used in the treatment of cardiac arrythmias, heart attack, and congestive heart failure. ␣-Blockers are often used in the treatment of prostate disease. It is of interest to analyze drugs that are prescribed purely for hypertension, purely for other indications, and those deliberately used to treat both hypertension and a concommitant condition. Unfortunately, our computerized pharmacy data do not have the indication of patient conditions. However, there is no reason to expect the relative percentage of individuals who were not hypertensive to change dra- Abbreviations as in Table 1 .
matically after the ALLHAT publication. Finally, we were unable to assess the effect of increased pharmacy market competition and promotion among these antihypertensive agents on their prescribing patterns. Despite these limitations, our findings establish that the response of physicians to new clinical evidence can be very rapid, irrespective of the cost or brand-name status of a drug.
